(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(2.10%) $83.06
(2.10%) $1.754
(1.32%) $2 242.00
(1.18%) $25.04
(1.37%) $922.20
(0.39%) $0.927
(0.87%) $10.86
(0.12%) $0.792
(0.13%) $92.56
Live Chart Being Loaded With Signals
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...
Stats | |
---|---|
Today's Volume | 45 471.00 |
Average Volume | 97 350.00 |
Market Cap | 65.06M |
EPS | $0 ( 2024-03-19 ) |
Next earnings date | ( $0 ) 2024-06-12 |
Last Dividend | $0.0470 ( 1995-06-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.70 |
ATR14 | $0.00500 (0.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Cannon Kara | Buy | 150 000 | Common Stock |
2024-02-21 | Cannon Kara | Buy | 10 640 | Common Stock |
2024-02-21 | Cannon Kara | Sell | 5 823 | Common Stock |
2024-02-23 | Eckert Patricia | Buy | 75 000 | Stock Option (to acquire shares of Common Stock) |
2024-01-31 | Pully Steven J | Buy | 79 365 | Common Stock |
INSIDER POWER |
---|
88.95 |
Last 85 transactions |
Buy: 4 325 861 | Sell: 177 248 |
Volume Correlation
Enzo Biochem Inc Correlation
10 Most Negative Correlations | |
---|---|
FPEI | -0.872 |
ASB-PE | -0.868 |
CUBB | -0.868 |
GL | -0.855 |
FLR | -0.852 |
NX | -0.843 |
MBI | -0.836 |
PQDI | -0.832 |
BGSF | -0.832 |
SPNT-PB | -0.825 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Enzo Biochem Inc Correlation - Currency/Commodity
Enzo Biochem Inc Financials
Annual | 2023 |
Revenue: | $31.06M |
Gross Profit: | $11.57M (37.24 %) |
EPS: | $-0.760 |
Q4 | 2023 |
Revenue: | $-19.66M |
Gross Profit: | $-24.72M (125.76 %) |
EPS: | $0.250 |
Q3 | 2023 |
Revenue: | $16.11M |
Gross Profit: | $1.64M (10.17 %) |
EPS: | $-0.300 |
Q2 | 2023 |
Revenue: | $16.34M |
Gross Profit: | $1.26M (7.71 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
Enzo Biochem Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0470 | 1995-06-29 |
Last Dividend | $0.0470 | 1995-06-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.81 | -- |
Div. Sustainability Score | 5.02 | |
Div.Growth Potential Score | 0.340 | |
Div. Directional Score | 2.68 | -- |
Year | Amount | Yield |
---|---|---|
1995 | $0.0470 | 0.58% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
MTR | Dividend Royal | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.333 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.545 | 1.500 | 5.06 | 7.59 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0444 | -1.500 | 9.26 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 33.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.455 | -0.909 | [0 - 20] |
debtEquityRatioTTM | 0.0621 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -1.203 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.348 | 1.000 | -8.96 | -8.96 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.10 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.977 | [0.5 - 2] |
Total Score | 5.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1.942 | 1.000 | 9.90 | 0 | [1 - 100] |
returnOnEquityTTM | 0.545 | 2.50 | 6.82 | 7.59 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.303 | -0.909 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0315 | 1.500 | -3.54 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.47 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.340 |
Enzo Biochem Inc
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators